These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37916262)

  • 1. Adult and pediatric physiologically-based biopharmaceutics modeling to explain lamotrigine immediate release absorption process.
    Caleffi-Marchesini ER; Herling AA; Macente J; Bonan RH; de Freitas Lima P; Moreno R; Alexandre V; Charbe NB; Borghi-Pangoni FB; Cristofoletti R; Diniz A
    CPT Pharmacometrics Syst Pharmacol; 2024 Feb; 13(2):208-221. PubMed ID: 37916262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring in vitro solubility of lamotrigine in physiologically mimetic conditions to prospect the in vivo dissolution in pediatric population.
    Caleffi-Marchesini ER; Borghi-Pangoni FB; Macente J; Chiamulera-Mantovani P; Mazucheli J; Cristofoletti R; Diniz A
    Biopharm Drug Dispos; 2023 Apr; 44(2):147-156. PubMed ID: 36951570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
    Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the Critical Variables of Azithromycin Oral Absorption Using In Vitro Tests and PBPK Modeling.
    Guimarães M; Somville P; Vertzoni M; Fotaki N
    J Pharm Sci; 2021 Dec; 110(12):3874-3888. PubMed ID: 34530004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Semi-Mechanistic Physiologically Based Biopharmaceutics Model to Describe Complex and Saturable Absorption of Metformin: Justification of Dissolution Specifications for Extended Release Formulation.
    Bhattiprolu AK; Kollipara S; Boddu R; Arumugam A; Khan SM; Ahmed T
    AAPS PharmSciTech; 2024 Aug; 25(7):193. PubMed ID: 39168956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards Virtual Bioequivalence Studies for Oral Dosage Forms Containing Poorly Water-Soluble Drugs: A Physiologically Based Biopharmaceutics Modeling (PBBM) Approach.
    Kambayashi A; Dressman JB
    J Pharm Sci; 2022 Jan; 111(1):135-145. PubMed ID: 34390740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Best Practices for Integration of Dissolution Data into Physiologically Based Biopharmaceutics Models (PBBM): A Biopharmaceutics Modeling Scientist Perspective.
    Kollipara S; Bhattiprolu AK; Boddu R; Ahmed T; Chachad S
    AAPS PharmSciTech; 2023 Feb; 24(2):59. PubMed ID: 36759492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case Studies.
    Mitra A; Parrott N; Miller N; Lloyd R; Tistaert C; Heimbach T; Ji Y; Kesisoglou F
    J Pharm Sci; 2020 Mar; 109(3):1380-1394. PubMed ID: 31778721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishing the Safe Space via Physiologically Based Biopharmaceutics Modeling. Case Study: Fevipiprant/QAW039.
    Kourentas A; Gajewska M; Lin W; Dhareshwar SS; Steib-Lauer C; Kulkarni S; Hirsch S; Heimbach T; Mueller-Zsigmondy M
    AAPS J; 2023 Feb; 25(1):25. PubMed ID: 36788163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance Evaluation of Montelukast Pediatric Formulations: Part II - a PBPK Modelling Approach.
    Guimarães M; Vertzoni M; Fotaki N
    AAPS J; 2022 Jan; 24(1):27. PubMed ID: 35013803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of fasted and fed bioequivalence for immediate release drug products using physiologically based biopharmaceutics modeling (PBBM).
    Jereb R; Kristl A; Mitra A
    Eur J Pharm Sci; 2020 Dec; 155():105554. PubMed ID: 32946959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
    Loisios-Konstantinidis I; Dressman J
    Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models.
    Hansmann S; Darwich A; Margolskee A; Aarons L; Dressman J
    J Pharm Pharmacol; 2016 Dec; 68(12):1501-1515. PubMed ID: 27781273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
    Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development.
    Wu D; Li M
    Pharm Res; 2023 Feb; 40(2):321-336. PubMed ID: 36076007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk assessment for extending the Biopharmaceutics Classification System-based biowaiver of immediate release dosage forms of fluconazole in adults to the paediatric population.
    Charoo NA; Cristofoletti R; Dressman JB
    J Pharm Pharmacol; 2015 Aug; 67(8):1156-69. PubMed ID: 25828546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs.
    Eckernäs E; Tannergren C
    Mol Pharm; 2021 Apr; 18(4):1699-1710. PubMed ID: 33720733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the Impact of Physiological Properties of the Gastrointestinal Tract On Drug In Vivo Performance Using Physiologically Based Biopharmaceutics Modeling and Virtual Clinical Trials.
    Jereb R; Opara J; Bajc A; Petek B
    J Pharm Sci; 2021 Aug; 110(8):3069-3081. PubMed ID: 33878322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies.
    Heimbach T; Kesisoglou F; Novakovic J; Tistaert C; Mueller-Zsigmondy M; Kollipara S; Ahmed T; Mitra A; Suarez-Sharp S
    J Pharm Sci; 2021 Dec; 110(12):3896-3906. PubMed ID: 34551349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP.
    Bermejo M; Hens B; Dickens J; Mudie D; Paixão P; Tsume Y; Shedden K; Amidon GL
    Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31963448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.